Latest News & Updates

Latest Articles
TKI Cessation Strategies Emerging for CML
TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.
PUBLISHED: December 04, 2016
Impressive Brentuximab Vedotin Data May Change Practice in CTCL
Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.
PUBLISHED: December 04, 2016
Survival Improves When Older Patients With AML Receive CPX-351 Before Transplant
CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.
PUBLISHED: December 03, 2016
Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.
PUBLISHED: December 03, 2016
Acalabrutinib Monotherapy Effective for Richter Transformation
The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.
PUBLISHED: December 03, 2016
Latest Peer Exchange Discussions
MDS: The Current Understanding in Molecular Testing and Biomarkers
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
ALK-Positive Lung Cancer
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefing™: Optimizing Treatment Strategies for Chemotherapy-Induced Nausea and VomitingDec 18, 20162.0
Evolving Management Options for Soft-Tissue SarcomasDec 21, 20161.0
Oncology Consultations®: Managing Patients with Radioactive Iodine – Refractory Differentiated Thyroid CancerDec 21, 20162.0
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Skin Cancer and Other Cutaneous MalignanciesDec 23, 20162.0
Publication Bottom Border
Border Publication